Analyst Benjamin Jackson CFA from Jefferies maintained a Buy rating on Galderma Group AG and increased the price target to CHF190.00 from CHF160.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Benjamin Jackson CFA has given his Buy rating due to a combination of factors that highlight Galderma Group AG’s potential for growth. He believes that the market’s current forecasts for Nemluvio in 2026 are overly conservative. His projections are 20% higher than the consensus, suggesting that the company’s sales could outperform expectations.
Furthermore, while there is some caution regarding Injectable Aesthetics, Jackson finds the 2026 Core EBITDA margin expectations reasonable. He anticipates that higher Nemluvio sales and further expansion in 2027 will support these margins. Consequently, he maintains a Buy rating with a price target increase of 19% to CHF190, justified by a premium multiple as the company continues to execute its strategy effectively.
In another report released on December 8, Barclays also maintained a Buy rating on the stock with a CHF155.00 price target.